Browse Studies — Arctuva

Phase 2

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (…

Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis

Estimated

~$10 – $8,750

Blueprint Medicines CorporationNCT04910685

An Observational Study in Patients With Indolent Systemic Mastocytosis

This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management o…

Indolent Systemic Mastocytosis

Estimated

~$10 – $1,050

Blueprint Medicines CorporationNCT07264959

Angioedema Biomarker Research Study

This clinical trial aims to evaluate and compare novel and commercially available diagnostic assays through blood tests for the differential diagnosis and comp…

AngioedemaAngioedemas, HereditaryUrticaria+5 more

Estimated

~$10 – $750

Foundation For Rare Disease ResearchNCT06210698

Phase 2

A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts…

MyelofibrosisIndolent Systemic Mastocytosis

Estimated

~$10 – $8,750

Telios Pharma, Inc.NCT04655118